On reading the article by Mostow et al1 in this issue of the Archives, it becomes apparent that several forces that will control our management of patients will converge on the issue of interferon for cutaneous T-cell lymphoma (CTCL). The New York Times (January 18, 1993:1) headline "New Standard for Drug Makers: Proving the Cure Is Worth the Cost" reflected Washington's interest in this and similar studies. Now, with an office in the White House, Hillary Clinton will take the lead in defining the integration of new therapies into the administration's health care policy. Prodding on this collision of interests is the revolution in T-cell biology that is bringing a hailstorm of biological insights into T-cell lymphoma faster than anyone can catch them or consider who should pay for them. These forces will encounter each other over the next few months, and therapy assessment will be a major issue.
Heald PW. Interferon and Hillary Clinton. Arch Dermatol. 1993;129(6):763-765. doi:10.1001/archderm.1993.01680270101014